Neovacs S.A. (ALNEV.PA)

EUR 1.11

(-11.15%)

Revenue Summary of Neovacs S.A.

  • Neovacs S.A.'s latest annual revenue in 2023 was 533.41 Thousand EUR , up 47868.71% from previous year.
  • Neovacs S.A.'s latest quarterly revenue in 2024 Q2 was 250.26 Thousand EUR , down 0.0% from previous quarter.
  • Neovacs S.A. reported a annual revenue of 1112.00 EUR in annual revenue 2022, down -95.07% from previous year.
  • Neovacs S.A. reported a annual revenue of 22.54 Thousand EUR in annual revenue 2021, down -24.32% from previous year.
  • Neovacs S.A. reported a quarterly revenue of 102.37 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
  • Neovacs S.A. reported a quarterly revenue of 533.41 Thousand EUR for 2023 FY, up 47868.71% from previous quarter.

Annual Revenue Chart of Neovacs S.A. (2023 - 2009)

Historical Annual Revenue of Neovacs S.A. (2023 - 2009)

Year Revenue Revenue Growth
2023 533.41 Thousand EUR 47868.71%
2022 1112.00 EUR -95.07%
2021 22.54 Thousand EUR -24.32%
2020 29.78 Thousand EUR -68.7%
2019 95.15 Thousand EUR -34.38%
2018 145 Thousand EUR 1029.81%
2017 12.83 Thousand EUR -96.25%
2016 342.42 Thousand EUR -70.17%
2015 1.14 Million EUR 709.45%
2014 141.82 Thousand EUR 374.65%
2013 29.88 Thousand EUR 149300.0%
2012 20.00 EUR -100.0%
2011 7.6 Million EUR 44321.39%
2010 17.12 Thousand EUR -95.37%
2009 370.19 Thousand EUR 0.0%

Peer Revenue Comparison of Neovacs S.A.

Name Revenue Revenue Difference
ABIONYX Pharma SA 4.64 Million EUR 88.504%
ABIVAX Société Anonyme 4.62 Million EUR 88.457%
Adocia SA 2.15 Million EUR 75.19%
Aelis Farma SA 9.05 Million EUR 94.109%
Biophytis S.A. - EUR -Infinity%
Advicenne S.A. 3.15 Million EUR 83.072%
genOway Société anonyme 20.04 Million EUR 97.339%
IntegraGen SA 12.53 Million EUR 95.745%
Medesis Pharma S.A. 300.03 Thousand EUR -77.784%
NFL Biosciences SA - EUR -Infinity%
Plant Advanced Technologies SA 1.68 Million EUR 68.278%
Quantum Genomics Société Anonyme 19.79 Thousand EUR -2594.544%
Sensorion SA 4.74 Million EUR 88.754%
Theranexus Société Anonyme 296.33 Thousand EUR -80.005%
TME Pharma N.V. 17 Thousand EUR -3037.718%
Valbiotis SA 4.73 Million EUR 88.73%
TheraVet SA 1.07 Million EUR 50.521%
Valerio Therapeutics Société anonyme 1.8 Million EUR 70.366%
argenx SE 1.13 Billion EUR 99.953%
BioSenic S.A. 543 Thousand EUR 1.766%
Celyad Oncology SA 102 Thousand EUR -422.953%
DBV Technologies S.A. - EUR -Infinity%
Galapagos NV 239.72 Million EUR 99.777%
Genfit S.A. 28.56 Million EUR 98.133%
GeNeuro SA - EUR -Infinity%
Hyloris Pharmaceuticals SA 2.08 Million EUR 74.441%
Innate Pharma S.A. 51.9 Million EUR 98.972%
Inventiva S.A. 17.47 Million EUR 96.948%
MaaT Pharma SA 2.22 Million EUR 76.059%
MedinCell S.A. 9.16 Million EUR 94.177%
Nanobiotix S.A. 30.05 Million EUR 98.225%
Onward Medical N.V. 532 Thousand EUR -0.265%
Oryzon Genomics S.A. 14.19 Million EUR 96.241%
OSE Immunotherapeutics SA 2.22 Million EUR 76.048%
Oxurion NV 263 Thousand EUR -102.818%
Pharming Group N.V. 245.31 Million EUR 99.783%
Poxel S.A. 1.98 Million EUR 73.074%
GenSight Biologics S.A. 1.26 Million EUR 57.9%
Transgene SA 1.18 Million EUR 54.948%
Financière de Tubize SA - EUR -Infinity%
UCB SA 5.25 Billion EUR 99.99%
Valneva SE 153.71 Million EUR 99.653%
Vivoryon Therapeutics N.V. -3.62 Million EUR 114.735%